Alkeon Capital Management Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Alkeon Capital Management reduced its stake in Celgene Corporation by 0.64% during the most recent quarter end. The investment management company now holds a total of 1,763,095 shares of Celgene Corporation which is valued at $212,770,305 after selling 11,350 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Celgene Corporation makes up approximately 4.14% of Alkeon Capital Management’s portfolio.

Other Hedge Funds, Including , Charter Research Investment Group boosted its stake in CELG in the latest quarter, The investment management firm added 90 additional shares and now holds a total of 19,834 shares of Celgene Corporation which is valued at $2,393,567. Celgene Corporation makes up approx 2.87% of Charter Research Investment Group’s portfolio.Profund Advisors reduced its stake in CELG by selling 17,899 shares or 3.86% in the most recent quarter. The Hedge Fund company now holds 445,641 shares of CELG which is valued at $53,949,299. Celgene Corporation makes up approx 2.61% of Profund Advisors’s portfolio. Baillie Gifford Co added CELG to its portfolio by purchasing 658,944 company shares during the most recent quarter which is valued at $79,119,406. Celgene Corporation makes up approx 0.13% of Baillie Gifford Co’s portfolio.

Celgene Corporation closed down -0.11 points or -0.09% at $121.97 with 50,48,365 shares getting traded on Monday. Post opening the session at $121.87, the shares hit an intraday low of $121.06 and an intraday high of $122.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Celgene Corporation reported $1.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $1.48. The company had revenue of $2983.00 million for the quarter, compared to analysts expectations of $2830.34 million. The company’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Celgene Corporation was Downgraded by Standpoint Research to ” Hold” on Nov 9, 2016. Mizuho Initiated Celgene Corporation on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $130.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.